A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination With Nivolumab Plus Ipilimumab in Patients With Renal Cell Carcinoma Previously Treated With Nivolumab Plus Ipilimumab
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Entinostat (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2019 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 12 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.
- 06 Sep 2018 Planned End Date changed from 1 Jun 2020 to 1 Aug 2020.